Table 2.

FR targeted nanoformulations designed for the treatment of inflammatory diseases.

Formulation		Disease	Stage	References
Folic acid coated nanoparticles	Folic acid-functionalized liposomes loaded with methotrexate	Rheumatoid arthritis	Pre-clinical	[81]
	Folic acid-functionalized lipid—polymeric nanoparticles loaded with methotrexate		Pre-clinical	[82]
	Folic acid-coated double liposomes loaded with both methrotrexate and prednisolone		Pre-clinical	[83]
	Folic acid-conjugated dendrimers loaded with methotrexate		Pre-clinical	[84]
	Folic acid-functionalized mesoporous silica-coated-gold nanoparticles loaded with methotrexate		Pre-clinical	[86]
	Folic acid-coated albumin nanoparticles loaded with etoricoxib		Pre-clinical	[87]
	Folic acid-coated pH-sensitive polyethylene glycol-chitosan-based nanoparticles loaded with methotrexate		Pre-clinical	[88]
Anti FRβ monoclonal antibody coated formulations	Anti-FRβ antibody-functionalized Cholesterol grafted chitosan nanoparticles loaded with methotrexate		Pre-clinical	[89]
Folic acid coated nanoparticles	Folic acid-coated poly(lactic-co-glycolic acid) nanoparticles loaded with resveratrol	Ulcerative Colitis	Pre-clinical	[90]